sirolimus (protein bound)

sir-OH-li-mus

Therapeutic Classification: antineoplastics, Immunosuppressant agents

Pharmacologic Classification: temporary class

High Alert

Locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor.

Acts as an inhibitor of mechanistic target of rapamycin kinase (mTOR), which reduces cell proliferation, angiogenesis, and glucose uptake. This formulation is bound to albumin, which may allow it to work differently and have a different side effect profile than other formulations of sirolimus.

Therapeutic effects:

Decreased tumor growth.

Absorption: IV administration results in complete bioavailability.

Distribution: Unknown.

Protein Binding: >99%.

Metabolism/Excretion: Primarily metabolized in the liver via the CYP3A4 isoenzyme. 91% excreted in the feces and 2% in the urine.

Half-Life: 59 hr.

(plasma concentrations)

ROUTE	ONSET	PEAK	DURATION
IV	rapid	end of infusion	unknown

Contraindicated in:

Hypersensitivity to sirolimus, other rapamycin derivatives, or albumin;
Severe hepatic impairment;
OB: Pregnancy;
Lactation: Lactation.

Use Cautiously in:

Diabetes;
Mild to moderate hepatic impairment (↓ dose);
Rep: Women and men of reproductive potential;
Pedi: Safety and effectiveness not established in children.

CV: edema, hypertension

Derm: alopecia, dry skin, nail disorder, pruritus, rash

EENT: blurred vision

Endo: hyperglycemia, hypoglycemia

F and E: dehydration, hypernatremia, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia

GI: ↑lipase, ↑liver enzymes, abdominal pain, constipation, diarrhea, dry mouth, hemorrhoids, hypoalbuminemia, mouth ulcers, nausea, stomatitis, vomiting

GU: ↑serum creatinine, infertility (men)

Hemat: anemia, hemorrhage, leukopenia, lymphopenia, neutropenia, thrombocytopenia

Metab: ↓appetite, hypercholesterolemia, hypertriglyceridemia, weight loss

MS: pain

Neuro: dizziness, dysgeusia, fatigue, headache, insomnia, peripheral neuropathy

Resp: cough, dyspnea, interstitial lung disease (ILD)

Misc: fever, infection, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS)

Drug-drug:

Strong CYP3A4 inhibitors or strong P-glycoprotein (P-gp) inhibitors may significantly ↑ levels and risk of toxicity; avoid concurrent use.
Strong CYP3A4 inducers or strong P-gp inducers may ↓ levels and effectiveness; avoid concurrent use.
Moderate CYP3A4 inhibitors or weak CYP3A4 inhibitors may ↑ levels and risk of toxicity; ↓ sirolimus dose.
Moderate CYP3A4 inducers or weak CYP3A4 inducers may ↓ levels and effectiveness.
May ↓ antibody response to and ↑ risk of adverse reactions to live-virus vaccines; avoid vaccination.

Drug-Food:

Grapefruit or grapefruit juice may ↑ levels and risk of toxicity; avoid concurrent use.

IV (Adults ): 100 mg/m² on Days 1 and 8 of each 21-day cycle; continue until disease progression or unacceptable toxicity. Concurrent use with moderate or weak CYP3A4 inhibitor: 56 mg/m² on Days 1 and 8 of each 21-day cycle; continue until disease progression or unacceptable toxicity.

Hepatic Impairment

IV (Adults ): Mild hepatic impairment (total bilirubin ≤upper limit of normal [ULN] with AST >ULN; or total bilirubin >1–1.5 times ULN with any AST: 75 mg/m² on Days 1 and 8 of each 21-day cycle; continue until disease progression or unacceptable toxicity. Moderate hepatic impairment (total bilirubin >1.5–3 times ULN with any AST): 56 mg/m² on Days 1 and 8 of each 21-day cycle; continue until disease progression or unacceptable toxicity.

Lyophilized powder for injection: 100 mg/vial

Assess for stomatitis within 8 wk of therapy. If Grade 2–3 stomatitis occurs, hold sirolimus until Grade ≤1; resume at same dose. If recurs, resume at ↓ dose. If Grade 4 stomatitis occurs, permanently discontinue sirolimus.
Monitor for infection (UTI, upper respiratory, sinusitis, skin, abdominal), including opportunistic infections. If Grade 3 infection occurs, hold sirolimus until resolved; resume at ↓ dose. If Grade 3 infection recurs, permanently discontinue sirolimus.
Monitor for ILD and noninfectious pneumonitis. If Grade 2 ILD or noninfectious pneumonitis occurs, hold sirolimus for up to 3 wk until Grade ≤1; resume at ↓ dose. If not improved to Grade ≤1 in 3 wk or Grade 2 recurs, permanently discontinue sirolimus. If Grade ≥3 ILD or noninfectious pneumonitis occurs, permanently discontinue sirolimus.
Monitor for signs and symptoms of hemorrhage. If Grade 2–3 hemorrhage occurs, hold sirolimus until Grade ≤1; resume at ↓ dose. If recurs, permanently discontinue sirolimus.
Monitor for hypersensitivity reactions, including anaphylaxis, during and for 2 hr after initial infusion and as clinically indicated after subsequent infusions. Keep resuscitation medication and equipment nearby. For Grade 2–3 hypersensitivity reactions, hold sirolimus until Grade ≤1; resume at ↓ dose. If recurs, permanently discontinue sirolimus.

Lab Test Considerations:

May cause myelosuppression. Obtain CBC with differential at baseline, every 2 mo for 1st year, and every 3 mo thereafter or as clinically indicated. Anemia: For Grade ≥2 anemia, hold sirolimus until hemoglobin ≥8 g/dL; resume at same dose. If recurs, resume at ↓ dose. Thrombocytopenia: For Grade 2 thrombocytopenia, hold sirolimus until platelets >100 × 10⁹/L; resume at same dose. For Grade ≥3 thrombocytopenia, hold sirolimus until platelets >100 × 10⁹/L; resume at ↓ dose. Neutropenia: For Grade 2–3 neutropenia, hold sirolimus until ANC ≥1.5 × 10⁹/L; resume at same dose. For Grade 4 neutropenia, hold sirolimus until ANC ≥1.5 × 10⁹/L; resume at ↓ dose.
May cause hypokalemia. Monitor potassium levels at baseline and use supplementation as indicated. For Grade 2 hypokalemia, hold sirolimus until Grade ≤1; resume at same dose. If recurs, resume at ↓ dose. For Grade ≥3 hypokalemia, hold sirolimus until Grade ≤1; resume at ↓ dose. If recurs, permanently discontinue sirolimus.
May cause hyperglycemia. Monitor fasting serum glucose at baseline. Monitor serum glucose every 3 mo during therapy or more frequently as indicated for patients with diabetes. For Grade ≥3 hyperglycemia, hold sirolimus until Grade ≤2; resume at ↓ dose.
Monitor hepatic function as clinically indicated.

High Alert: Do not confuse sirolimus with silodosin.
All age-appropriate vaccinations should be completed per current guidelines prior to therapy initiation.
Follow applicable special handling and disposal procedures for hazardous drugs.
Dose adjustments for adverse reactions: 1st dose reduction:↓ to 75 mg/m². 2nd dose reduction: ↓to 56 mg/m². 3rd dose reduction:↓ to 45 mg/m².

IV Administration:

Explain purpose and side effects of medication to patient. Advise patient to read Patient Information before starting therapy.
Advise patient to discontinue sirolimus and notify health care professional immediately for symptoms of hypersensitivity (rash, difficulty breathing, flushing, chest pain, angioedema), severe bleeding or injury, ILD (shortness of breath), or serious infection.
Inform patient of the need to monitor labs frequently throughout therapy.
Inform patient to avoid live vaccines and contact with those who have received live vaccines during therapy.
Inform patient of ↑ risk of contracting infections during therapy.
Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult health care professional before taking other medications.
Rep: May cause fetal harm. Advise women of reproductive potential to use effective contraception during therapy and for 12 wk after last dose. Advise patient not to breastfeed during therapy or for 2 wk after last dose and to notify health care professional if pregnancy is planned or suspected. May cause female and male infertility.

↓tumor growth.

Fyarro

NDC Code

0008- Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
- 0008-1041- Rapamune
  - 0008-1041-05- 100 TABLET, SUGAR COATED in 1 BOTTLE (0008-1041-05)

0008- Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
- 0008-1042- Rapamune
  - 0008-1042-05- 100 TABLET, SUGAR COATED in 1 BOTTLE (0008-1042-05)

0904- Major Pharmaceuticals
- 0904-7248- Sirolimus
  - 0904-7248-04- 30 BLISTER PACK in 1 CARTON (0904-7248-04) / 1 TABLET in 1 BLISTER PACK

16714- NORTHSTAR RX LLC
- 16714-187- sirolimus
  - 16714-187-01- 100 TABLET, FILM COATED in 1 BOTTLE (16714-187-01)

16714- NORTHSTAR RX LLC
- 16714-188- sirolimus
  - 16714-188-01- 100 TABLET, FILM COATED in 1 BOTTLE (16714-188-01)

16714- NORTHSTAR RX LLC
- 16714-189- sirolimus
  - 16714-189-01- 100 TABLET, FILM COATED in 1 BOTTLE (16714-189-01)

31722- Camber Pharmaceuticals, Inc.
- 31722-316- SIROLIMUS
  - 31722-316-31- 1 CARTON in 1 KIT (31722-316-31) / 1 BOTTLE, GLASS in 1 CARTON (31722-316-60) / 60 mL in 1 BOTTLE, GLASS

42513- Livzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd.
- 42513-0013-
  - 42513-0013-1- 1 BAG in 1 CARTON (42513-0013-1) / 1 BOTTLE in 1 BAG / 1 BAG in 1 BOTTLE / 1 kg in 1 BAG

42513- Livzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd.
- 42513-0013-
  - 42513-0013-2- 1 BAG in 1 CARTON (42513-0013-2) / 1 BOTTLE in 1 BAG / 1 BAG in 1 BOTTLE / 3 kg in 1 BAG

42513- Livzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd.
- 42513-0013-
  - 42513-0013-3- 2 BAG in 1 CARTON (42513-0013-3) / 1 BOTTLE in 1 BAG / 1 BAG in 1 BOTTLE / 3 kg in 1 BAG

42816- Pfizer Ireland Pharmaceuticals Unlimited Company
- 42816-1040-
  42816-1040-1- 1 BAG in 1 DRUM (42816-1040-1) / 33588 TABLET, SUGAR COATED in 1 BAG

42816- Pfizer Ireland Pharmaceuticals Unlimited Company
- 42816-1041-
  42816-1041-1- 1 BAG in 1 DRUM (42816-1041-1) / 33588 TABLET, SUGAR COATED in 1 BAG

42816- Pfizer Ireland Pharmaceuticals Unlimited Company
- 42816-1042-
  42816-1042-1- 1 BAG in 1 DRUM (42816-1042-1) / 33588 TABLET, SUGAR COATED in 1 BAG

50268- AvPAK
- 50268-718- Sirolimus
  50268-718-13- 30 BLISTER PACK in 1 BOX (50268-718-13) / 1 TABLET in 1 BLISTER PACK (50268-718-11)

51187- Hisun Pharmaceutical (Hangzhou) Co., Ltd.
- 51187-0010-
  - 51187-0010-1- .5 kg in 1 DRUM (51187-0010-1)

51187- Hisun Pharmaceutical (Hangzhou) Co., Ltd.
- 51187-0010-
  51187-0010-2- 2 kg in 1 DRUM (51187-0010-2)

55111- Dr. Reddy's Laboratories Limited
- 55111-653- Sirolimus
  55111-653-01- 100 TABLET in 1 BOTTLE (55111-653-01)

55111- Dr. Reddy's Laboratories Limited
- 55111-653- Sirolimus
  - 55111-653-30- 30 TABLET in 1 BOTTLE (55111-653-30)

55111- Dr. Reddy's Laboratories Limited
- 55111-654- Sirolimus
  - 55111-654-01- 100 TABLET in 1 BOTTLE (55111-654-01)

55111- Dr. Reddy's Laboratories Limited
- 55111-654- Sirolimus
  - 55111-654-30- 30 TABLET in 1 BOTTLE (55111-654-30)

55486- Curia Italy S.r.l.
- 55486-1571-
  - 55486-1571-0- 4 kg in 1 DRUM (55486-1571-0)

55500- North China Pharmaceutical Huasheng Co. Ltd.
- 55500-0011-
  55500-0011-1- 1 kg in 1 CARTON (55500-0011-1)

55500- North China Pharmaceutical Huasheng Co. Ltd.
- 55500-0011-
  55500-0011-2- 1 kg in 1 CARTON (55500-0011-2)

56125- Novo Nordisk Production Ireland Limited
- 56125-800-
  56125-800-01- 66.7 kg in 1 CAN (56125-800-01)

57885- Chongqing Daxin Pharmaceutical Co. Ltd.
- 57885-0014-
  57885-0014-2- 10 kg in 1 BAG (57885-0014-2)

59573- Fujian Kerui Pharmaceutical Co., Ltd.
- 59573-0004-
  59573-0004-1- 500 g in 1 BAG (59573-0004-1)

59762- Mylan Pharmaceuticals Inc.
- 59762-1001- Sirolimus
  59762-1001-1- 100 TABLET, SUGAR COATED in 1 BOTTLE (59762-1001-1)

59762- Mylan Pharmaceuticals Inc.
- 59762-1002- Sirolimus
  - 59762-1002-1- 100 TABLET, SUGAR COATED in 1 BOTTLE (59762-1002-1)

59762- Mylan Pharmaceuticals Inc.
- 59762-1003- Sirolimus
  - 59762-1003-1- 100 TABLET, SUGAR COATED in 1 BOTTLE (59762-1003-1)

59762- Mylan Pharmaceuticals Inc.
- 59762-1205- Sirolimus
  - 59762-1205-6- 1 CARTON in 1 KIT (59762-1205-6) / 1 BOTTLE, GLASS in 1 CARTON (59762-1205-4) / 60 mL in 1 BOTTLE, GLASS

60505- Apotex Corp
- 60505-6197- Sirolimus
  - 60505-6197-2- 1 BOTTLE, GLASS in 1 CARTON (60505-6197-2) / 60 mL in 1 BOTTLE, GLASS

62991- LETCO MEDICAL, LLC
- 62991-3184-
  - 62991-3184-1- 1 g in 1 JAR (62991-3184-1)

62991- LETCO MEDICAL, LLC
- 62991-3184-
  62991-3184-2- 5 g in 1 JAR (62991-3184-2)

65727- Biocon Limited
- 65727-013-
  65727-013-01- 25 kg in 1 DRUM (65727-013-01)

65841- Zydus Lifesciences Limited
- 65841-771- sirolimus
  65841-771-01- 100 TABLET, FILM COATED in 1 BOTTLE (65841-771-01)

65841- Zydus Lifesciences Limited
- 65841-771- sirolimus
  - 65841-771-05- 500 TABLET, FILM COATED in 1 BOTTLE (65841-771-05)

65841- Zydus Lifesciences Limited
- 65841-771- sirolimus
  - 65841-771-06- 30 TABLET, FILM COATED in 1 BOTTLE (65841-771-06)

65841- Zydus Lifesciences Limited
- 65841-771- sirolimus
  - 65841-771-10- 1000 TABLET, FILM COATED in 1 BOTTLE (65841-771-10)

65841- Zydus Lifesciences Limited
- 65841-771- sirolimus
  - 65841-771-16- 90 TABLET, FILM COATED in 1 BOTTLE (65841-771-16)

65841- Zydus Lifesciences Limited
- 65841-771- sirolimus
  - 65841-771-77- 10 BLISTER PACK in 1 CARTON (65841-771-77) / 10 TABLET, FILM COATED in 1 BLISTER PACK (65841-771-30)

65841- Zydus Lifesciences Limited
- 65841-772- sirolimus
  - 65841-772-01- 100 TABLET, FILM COATED in 1 BOTTLE (65841-772-01)

65841- Zydus Lifesciences Limited
- 65841-772- sirolimus
  - 65841-772-77- 10 BLISTER PACK in 1 CARTON (65841-772-77) / 10 TABLET, FILM COATED in 1 BLISTER PACK (65841-772-30)

65841- Zydus Lifesciences Limited
- 65841-773- sirolimus
  - 65841-773-01- 100 TABLET, FILM COATED in 1 BOTTLE (65841-773-01)

65841- Zydus Lifesciences Limited
- 65841-773- sirolimus
  - 65841-773-77- 10 BLISTER PACK in 1 CARTON (65841-773-77) / 10 TABLET, FILM COATED in 1 BLISTER PACK (65841-773-30)

66689- VistaPharm, LLC
- 66689-347- Sirolimus
  - 66689-347-02- 1 CARTON in 1 KIT (66689-347-02) / 1 BOTTLE in 1 CARTON / 60 mL in 1 BOTTLE

67877- Ascend Laboratories, LLC
- 67877-746- Sirolimus
  - 67877-746-01- 100 TABLET in 1 BOTTLE (67877-746-01)

67877- Ascend Laboratories, LLC
- 67877-746- Sirolimus
  - 67877-746-05- 500 TABLET in 1 BOTTLE (67877-746-05)

67877- Ascend Laboratories, LLC
- 67877-746- Sirolimus
  - 67877-746-30- 30 TABLET in 1 BOTTLE (67877-746-30)

67877- Ascend Laboratories, LLC
- 67877-746- Sirolimus
  - 67877-746-38- 100 BLISTER PACK in 1 CARTON (67877-746-38) / 10 TABLET in 1 BLISTER PACK (67877-746-33)

67877- Ascend Laboratories, LLC
- 67877-747- Sirolimus
  - 67877-747-01- 100 TABLET in 1 BOTTLE (67877-747-01)

67877- Ascend Laboratories, LLC
- 67877-747- Sirolimus
  - 67877-747-05- 500 TABLET in 1 BOTTLE (67877-747-05)

67877- Ascend Laboratories, LLC
- 67877-747- Sirolimus
  - 67877-747-30- 30 TABLET in 1 BOTTLE (67877-747-30)

67877- Ascend Laboratories, LLC
- 67877-747- Sirolimus
  - 67877-747-38- 100 BLISTER PACK in 1 CARTON (67877-747-38) / 10 TABLET in 1 BLISTER PACK (67877-747-33)

67877- Ascend Laboratories, LLC
- 67877-748- Sirolimus
  - 67877-748-01- 100 TABLET in 1 BOTTLE (67877-748-01)

67877- Ascend Laboratories, LLC
- 67877-748- Sirolimus
  - 67877-748-05- 500 TABLET in 1 BOTTLE (67877-748-05)

67877- Ascend Laboratories, LLC
- 67877-748- Sirolimus
  - 67877-748-30- 30 TABLET in 1 BOTTLE (67877-748-30)

67877- Ascend Laboratories, LLC
- 67877-748- Sirolimus
  - 67877-748-38- 100 BLISTER PACK in 1 CARTON (67877-748-38) / 10 TABLET in 1 BLISTER PACK (67877-748-33)

68084- American Health Packaging
- 68084-915- Sirolimus
  - 68084-915-25- 30 BLISTER PACK in 1 BOX, UNIT-DOSE (68084-915-25) / 1 TABLET in 1 BLISTER PACK (68084-915-95)

68254- CONCORD BIOTECH LTD
- 68254-1006-
  - 68254-1006-2- 1 BAG in 1 BOTTLE (68254-1006-2) / 1 kg in 1 BAG

68382- Zydus Pharmaceuticals USA Inc.
- 68382-351- sirolimus
  68382-351-01- 100 TABLET, FILM COATED in 1 BOTTLE (68382-351-01)

68382- Zydus Pharmaceuticals USA Inc.
- 68382-351- sirolimus
  - 68382-351-77- 10 BLISTER PACK in 1 CARTON (68382-351-77) / 10 TABLET, FILM COATED in 1 BLISTER PACK (68382-351-30)

68382- Zydus Pharmaceuticals USA Inc.
- 68382-352- sirolimus
  - 68382-352-01- 100 TABLET, FILM COATED in 1 BOTTLE (68382-352-01)

68382- Zydus Pharmaceuticals USA Inc.
- 68382-352- sirolimus
  - 68382-352-77- 10 BLISTER PACK in 1 CARTON (68382-352-77) / 10 TABLET, FILM COATED in 1 BLISTER PACK (68382-352-30)

68382- Zydus Pharmaceuticals USA Inc.
- 68382-520- sirolimus
  - 68382-520-01- 100 TABLET, FILM COATED in 1 BOTTLE (68382-520-01)

68382- Zydus Pharmaceuticals USA Inc.
- 68382-520- sirolimus
  - 68382-520-05- 500 TABLET, FILM COATED in 1 BOTTLE (68382-520-05)

68382- Zydus Pharmaceuticals USA Inc.
- 68382-520- sirolimus
  - 68382-520-06- 30 TABLET, FILM COATED in 1 BOTTLE (68382-520-06)

68382- Zydus Pharmaceuticals USA Inc.
- 68382-520- sirolimus
  - 68382-520-10- 1000 TABLET, FILM COATED in 1 BOTTLE (68382-520-10)

68382- Zydus Pharmaceuticals USA Inc.
- 68382-520- sirolimus
  - 68382-520-16- 90 TABLET, FILM COATED in 1 BOTTLE (68382-520-16)

68382- Zydus Pharmaceuticals USA Inc.
- 68382-520- sirolimus
  - 68382-520-77- 10 BLISTER PACK in 1 CARTON (68382-520-77) / 10 TABLET, FILM COATED in 1 BLISTER PACK (68382-520-30)

68462- Glenmark Pharmaceuticals Inc., USA
- 68462-682- sirolimus
  - 68462-682-01- 100 TABLET, FILM COATED in 1 BOTTLE (68462-682-01)

68462- Glenmark Pharmaceuticals Inc., USA
- 68462-683- sirolimus
  - 68462-683-01- 100 TABLET, FILM COATED in 1 BOTTLE (68462-683-01)

68462- Glenmark Pharmaceuticals Inc., USA
- 68462-684- sirolimus
  - 68462-684-01- 100 TABLET, FILM COATED in 1 BOTTLE (68462-684-01)

69238- Amneal Pharmaceuticals NY LLC
- 69238-1594- Sirolimus
  - 69238-1594-3- 1 CARTON in 1 KIT (69238-1594-3) / 1 BOTTLE, GLASS in 1 CARTON (69238-1594-6) / 60 mL in 1 BOTTLE, GLASS

70518- REMEDYREPACK INC.
- 70518-3546- Sirolimus
  - 70518-3546-0- 100 POUCH in 1 BOX (70518-3546-0) / 1 TABLET in 1 POUCH (70518-3546-1)

70518- REMEDYREPACK INC.
- 70518-4194- Sirolimus
  - 70518-4194-0- 100 POUCH in 1 BOX (70518-4194-0) / 1 TABLET, SUGAR COATED in 1 POUCH (70518-4194-1)

71052- Darmerica, LLC
- 71052-202-
  - 71052-202-01- .001 kg in 1 BOTTLE (71052-202-01)

71052- Darmerica, LLC
- 71052-202-
  71052-202-05- .005 kg in 1 BOTTLE (71052-202-05)

71052- Darmerica, LLC
- 71052-202-
  71052-202-10- .01 kg in 1 PACKAGE (71052-202-10)

71052- Darmerica, LLC
- 71052-202-
  71052-202-25- .025 kg in 1 CONTAINER (71052-202-25)

72205- Novadoz Pharmaceuticals LLC
- 72205-099- sirolimus
  72205-099-78- 1 BOTTLE, GLASS in 1 CARTON (72205-099-78) / 60 mL in 1 BOTTLE, GLASS

73212- Qingdao Biopeptek Co., Ltd.
- 73212-019-
  - 73212-019-01- 1 g in 1 BOTTLE (73212-019-01)

73212- Qingdao Biopeptek Co., Ltd.
- 73212-019-
  73212-019-05- 5 g in 1 BOTTLE (73212-019-05)

73212- Qingdao Biopeptek Co., Ltd.
- 73212-019-
  73212-019-10- 10 g in 1 BOTTLE (73212-019-10)

73212- Qingdao Biopeptek Co., Ltd.
- 73212-019-
  73212-019-11- 50 g in 1 BOTTLE (73212-019-11)

73212- Qingdao Biopeptek Co., Ltd.
- 73212-019-
  73212-019-12- 100 g in 1 BOTTLE (73212-019-12)

73377- AX Pharmaceutical Corp
- 73377-024-
  73377-024-01- 10 g in 1 JAR (73377-024-01)

73377- AX Pharmaceutical Corp
- 73377-024-
  73377-024-02- 1 g in 1 JAR (73377-024-02)

73377- AX Pharmaceutical Corp
- 73377-024-
  73377-024-03- 100 g in 1 JAR (73377-024-03)

73377- AX Pharmaceutical Corp
- 73377-024-
  73377-024-04- 50 g in 1 JAR (73377-024-04)

73377- AX Pharmaceutical Corp
- 73377-024-
  73377-024-05- 5 g in 1 JAR (73377-024-05)

73377- AX Pharmaceutical Corp
- 73377-024-
  73377-024-06- 1.6 g in 1 JAR (73377-024-06)

73683- Nobelpharma America, LLC
- 73683-101- HYFTOR
  73683-101-10- 1 TUBE in 1 CARTON (73683-101-10) / 10 g in 1 TUBE

80803- Aadi Bioscience
- 80803-153- FYARRO
  - 80803-153-50- 1 VIAL, SINGLE-USE in 1 CARTON (80803-153-50) / 20 mL in 1 VIAL, SINGLE-USE

82393- Pharma Source Direct, Inc.
- 82393-501-
  - 82393-501-04- .001 kg in 1 CONTAINER (82393-501-04)

82393- Pharma Source Direct, Inc.
- 82393-501-
  82393-501-05- .005 kg in 1 CONTAINER (82393-501-05)

82393- Pharma Source Direct, Inc.
- 82393-501-
  82393-501-07- .025 kg in 1 CONTAINER (82393-501-07)

82393- Pharma Source Direct, Inc.
- 82393-501-
  82393-501-08- .1 kg in 1 CONTAINER (82393-501-08)

84517- Zhejiang Wild Wind Pharmaceutical Co.,Ltd.
- 84517-032-
  84517-032-01- 1 kg in 1 BAG (84517-032-01)

85705- Sumar Biotech LLP
- 85705-001-
  85705-001-01- 5 g in 1 BAG (85705-001-01)

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇

Time/Action Profile ⬆ ⬇

Contraind./Precautions ⬆ ⬇

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Code ⬆